Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors

Yang Yao, Minyue Zhang, Di Liu, Xiaoni Liu, Quanwei Li, Xiaojun Wang

Open source

DOI
10.1007/s12094-024-03596-0
Published
2024-08-17
Container
Clinical and Translational Oncology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12094-024-03596-0,
  title = {Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors},
  author = {Yang Yao and Minyue Zhang and Di Liu and Xiaoni Liu and Quanwei Li and Xiaojun Wang},
  year = {2024},
  journal = {Clinical and Translational Oncology},
  doi = {10.1007/s12094-024-03596-0},
  url = {https://doi.org/10.1007/s12094-024-03596-0}
}

RIS

TY  - JOUR
TI  - Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors
AU  - Yang Yao
AU  - Minyue Zhang
AU  - Di Liu
AU  - Xiaoni Liu
AU  - Quanwei Li
AU  - Xiaojun Wang
PY  - 2024
JO  - Clinical and Translational Oncology
DO  - 10.1007/s12094-024-03596-0
UR  - https://doi.org/10.1007/s12094-024-03596-0
ER  - 

APA

Yao, Y., Zhang, M., Liu, D., Liu, X., Li, Q., & Wang, X. (2024). Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03596-0

Source records